文献速递外周动脉疾病

BioMimics 3D支架治疗股腘病变:MIMICS-2试验两年结果

Treatment of Femoropopliteal Lesions With the BioMimics 3D Vascular Stent System: Two-Year Results From the MIMICS-2 Trial.
PubMed 文献 · J Endovasc Ther · 2020-12-17

MIMICS-2单臂试验纳入271例股腘动脉病变患者,评估BioMimics 3D镍钛支架的安全性和有效性。12个月主要支架通畅率为73.1%,超过预设目标66%;30天无主要不良事件率为99.6%,超过预设目标88%。24个月免于临床驱动的靶病变血运重建率为83.0%,无支架断裂。

要点

  • 12个月主要支架通畅率73.1%,超过预设目标66%
  • 30天无主要不良事件率99.6%,超过预设目标88%
  • 24个月免于临床驱动的靶病变血运重建率83.0%

核心结论

  • BioMimics 3D支架在24个月内对症状性外周动脉疾病患者的股腘病变提供安全有效的治疗。

研究设计与样本

  • 前瞻性单臂MIMICS-2研究,纳入271例股腘动脉新发病变患者,平均年龄68.4±9.5岁,180例男性,来自43个中心(美国31个n=162,德国6个n=78,日本6个n=31)。
  • 平均病变长度81.2±38.4 mm,30.0%为完全闭塞,45.9%为中度至重度钙化。
  • 主要安全性和有效性终点在1年时与VIVA Physicians组织预设的目标性能目标(OPG)比较。

主要发现

  • 12个月主要支架通畅率73.1%(182/249,95%CI 67.3%至78.2%),超过OPG 66%。
  • 30天无主要不良事件(MAE)率99.6%(268/269,95%CI 97.7%至100%),超过OPG 88%。
  • Kaplan-Meier估计12个月和24个月免于主要通畅丧失分别为83.1%和70.2%,免于MAE分别为86.9%和79.2%,免于临床驱动的靶病变血运重建分别为88.0%和83.0%。
  • 24个月时88.2%患者Rutherford分级改善≥1级;踝肱指数>0.9者占64.4%,基线为11.3%。
  • 无支架断裂病例。

关键数值与推荐

  • 12个月主要支架通畅率73.1%(95%CI 67.3%至78.2%),OPG为66%。
  • 30天无MAE率99.6%(95%CI 97.7%至100%),OPG为88%。
  • 24个月免于临床驱动的靶病变血运重建率83.0%。

临床怎么用

  • BioMimics 3D支架可作为症状性外周动脉疾病患者股腘病变的治疗选择,2年随访显示安全有效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report the safety and effectiveness outcomes through 2 years of the BioMimics 3D Vascular Stent System in the treatment of symptomatic patients with atherosclerotic femoropopliteal disease. MATERIALS AND METHODS: The tubular, nitinol BioMimics 3D stent, which was designed to impart a helical shape to the arterial segment, was implanted in 271 patients (mean age 68.4±9.5 years; 180 men) with de novo femoropopliteal lesions enrolled at 43 investigational sites [31 US (n=162), 6 German (n=78), and 6 Japanese (n=31)] in the prospective, single-arm MIMICS-2 investigational device exemption trial (ClinicalTrials.gov identifier NCT02400905) between June 2015 and October 2016. Mean lesion length was 81.2±38.4 mm, 30.0% of patients had total occlusions, and 45.9% had moderate to severe calcification. Primary safety and effectiveness endpoints were compared at 1 year with prespecified objective performance goals (OPGs) set by the VIVA Physicians organization. Outcomes through 2 years are reported. RESULTS: The primary effectiveness endpoint of 12-month primary stent patency was met by 182 of 249 patients (73.1%, 95% CI 67.3% to 78.2%), exceeding the OPG of 66%. The primary safety endpoint of 30-day freedom from major adverse events (MAEs) was met in 268 of 269 patients (99.6%, 95% CI 97.7% to 100%), exceeding the OPG of 88%. Kaplan-Meier estimates of freedom from loss of primary patency were 83.1% at 12 months and 70.2% at 24 months, freedom from MAEs estimates were 86.9% at 12 months and 79.2% at 24 months, and freedom from clinically-driven target lesion revascularization estimates were 88.0% at 12 months and 83.0% at 24 months. At 24 months, 88.2% of patients showed improvement of ≥1 Rutherford category; the ankle-brachial index was >0.9 for 64.4% vs 11.3% at baseline. There were no cases of stent fracture. CONCLUSION: Through 24 months, the BioMimics 3D Vascular Stent System provided safe and effective treatment for femoropopliteal lesions in patients with symptomatic peripheral artery disease.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Sullivan TM, Zeller T, Nakamura M, et al. Treatment of Femoropopliteal Lesions With the BioMimics 3D Vascular Stent System: Two-Year Results From the MIMICS-2 Trial. J Endovasc Ther. 2020. PMID: 33331207. doi:10.1177/1526602820980419

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。